Drug intelligence / Profile preview

SAG21K

Development stage: Preclinical
Lead developer: Tocris
Modality: Small Molecules
Administration: Oral, Intraperitoneal, Local (hydrogel-based/topical Application)

Overview

SAG21K is a potent, brain-penetrant, and orally bioavailable small molecule **agonist of the Hedgehog signaling pathway**. It acts primarily by directly activating the Smoothened (Smo) receptor, leading to downstream induction of Gli1 transcription and Hedgehog target gene expression. SAG21K has been studied in preclinical models for its capacity to stimulate Hedgehog signaling in a tissue-selective manner and exhibits protective effects in disease models such as colitis and nerve injury. Localized administration (e.g., via fibrin hydrogels) enables targeted activation with minimized systemic exposure.

Targets

SMO (Smoothened)

Beyond the preview

Go deeper on SAG21K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAG21K.

Explore the full profile